Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA Class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatm
about
Regulation of adaptive immunity; the role of interleukin-10Evaluation of Study and Patient Characteristics of Clinical Studies in Primary Progressive Multiple Sclerosis: A Systematic ReviewPrimary progressive multiple sclerosis: current therapeutic strategies and future perspectivesNeuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications.Restoring the balance: immunotherapeutic combinations for autoimmune disease'Multi-epitope-targeted' immune-specific therapy for a multiple sclerosis-like disease via engineered multi-epitope protein is superior to peptidesSequential transcriptional changes dictate safe and effective antigen-specific immunotherapy.The immunological basis for treatment of multiple sclerosis.Modification of Multiple Sclerosis Phenotypes by African Ancestry at HLAClinical trials in progressive multiple sclerosis: lessons learned and future perspectivesThe adaptive immune system in diseases of the central nervous system.Immune modulating peptides for the treatment and suppression of multiple sclerosis.TGF-β signaling via Smad4 drives IL-10 production in effector Th1 cells and reduces T-cell trafficking in EAEPharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis.H(1)R expression by CD11B(+) cells is not required for susceptibility to experimental allergic encephalomyelitisTolerance to melanin-associated antigen in autoimmune uveitis is mediated by CD4+CD25+ T-regulatory cellsAntigen-specific therapy of multiple sclerosis: the long-sought magic bullet.Regulatory and pro-inflammatory phenotypes of myelin basic protein-autoreactive T cells in multiple sclerosis.DNA vaccines for autoimmune diseases.Novel targeted therapies for autoimmunity.Combination peptide immunotherapy suppresses antibody and helper T-cell responses to the RhD protein in HLA-transgenic mice.Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosisBack to the future for multiple sclerosis therapy: focus on current and emerging disease-modifying therapeutic strategies.Immunomodulatory drug treatment in multiple sclerosis.Antigen-specific immunotherapy of autoimmune and allergic diseasesMultiple sclerosis: a supplement on the disease state, current therapies, and investigational treatments.Immune-mediated and autoimmune myocarditis: clinical presentation, diagnosis and management.Antigen-specific tolerization approaches in multiple sclerosis.Neuroproteomics and microRNAs studies in multiple sclerosis: transforming research and clinical knowledge in biomarker research.Dendritic cells as therapeutic targets in neuroinflammation.Further understanding of the immunopathology of multiple sclerosis: impact on future treatments.Progressive MS trials: Lessons learned.Antigen-specific therapy of rheumatoid arthritisAn Examination of the Mechanisms by which Neural Precursors Augment Recovery following Spinal Cord Injury: A Key Role for Remyelination
P2860
Q21131215-8789D7D7-E895-4F97-8DC4-B1705B9D0662Q26782408-8E6A5EE2-73FA-4AB4-80FE-F35C7D5A3DF3Q29030703-F6E67BC1-C60B-48B2-8444-788A2113BCE3Q30699740-4C490B2A-E5C5-44DA-BA3C-A23C40E07986Q33555986-26E606D8-5F15-4D8F-BEF5-BD789E9E856FQ34091080-E76321DF-878A-4C63-BDBE-3CFD1E63096EQ34205503-1247E6FE-0551-42DC-B3AC-97835931BDC0Q34582895-EDA7AC8C-7616-4459-8336-66B5BD98DDBEQ35101408-C059D555-97E3-4BFF-85AA-997488993960Q35182733-F8768CA1-FA18-4B08-A498-11772147A3C2Q35858036-110EE4E4-D7FF-4F90-AC0E-E81679F689E0Q36151968-66A92D49-520B-4E26-A8F2-AA7BD0FF80F3Q36340416-BC62D8B2-56F3-4A4A-B34E-D678CB74E132Q36353053-FE14CEA4-5E52-4FB8-B126-E808DDF73212Q36374681-7DFCA2DD-E5BD-4875-9A41-61CFEC3FF917Q36943091-5B32BDA3-97EC-4AC4-A70E-2CE6238C1DF9Q36963194-8967A027-AD32-4921-9349-4DDFD7310045Q37426985-0AF78D9E-3F62-446E-BE47-B58768D45D7CQ37590340-E6900A54-DE06-4FE1-9D2F-CB4A791DAABAQ37614638-D1370332-9C85-4246-9311-852378254A38Q37618940-B611CBE4-5197-49B0-855C-2B45437A7B7DQ37679881-8035AF44-FB36-4749-872F-0A1F4841E6A2Q37773270-2DBEC1E7-45E4-4F91-A486-DE8B6DEFE785Q37785554-8DC8D00C-DCA1-49C5-AE80-5959D001BA86Q37790023-FE12B13F-F511-4739-BBCE-9487FB918544Q37867269-B9B85BAB-9E68-4075-BCFF-C5ED610BBB34Q38056870-8670CA0C-B0DA-468B-9DA1-528D544DA18AQ38154948-E09EFB0F-8E5C-4187-8375-0401FF5F393CQ38610689-FA32E902-E492-4113-B6A5-46C9D41CB6D5Q38771884-3A3A2A13-50DC-4330-97CE-9C8BDCAED05AQ38837294-DB220E90-2CC4-4F9A-99D9-7050FCF7A8A9Q47892257-DB1C8791-8A54-4931-8E38-EF19CB0A7C14Q57674015-C6498AC0-B071-4F17-BE53-0DDF7617E04EQ57838894-3089BCC5-57D9-4EFE-9A5C-AD35F50F2EB9
P2860
Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA Class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatm
description
2006 nî lūn-bûn
@nan
2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Intravenous synthetic peptide ...... nd 5 years of follow-up treatm
@nl
type
label
Intravenous synthetic peptide ...... nd 5 years of follow-up treatm
@nl
prefLabel
Intravenous synthetic peptide ...... nd 5 years of follow-up treatm
@nl
P2093
P2860
P1476
Intravenous synthetic peptide ...... 5 years of follow-up treatment
@en
P2093
P2860
P304
P356
10.1111/J.1468-1331.2006.01533.X
P407
P577
2006-08-01T00:00:00Z